Crispr Therapeutics (CRSP) Stock
Gene editing biotech developing treatments for genetic diseases. Here's the price, business snapshot, and what's worth knowing about Crispr Therapeutics in June 2026.
CRISPR Therapeutics AG (CRSP) is a biotechnology company developing gene‑editing therapies based on the CRISPR/Cas9 platform. The firm focuses on both ex vivo and in vivo programmes, with clinical-stage candidates targeting genetic blood disorders, certain cancers and other rare diseases. CRISPR’s progress depends on successful clinical trials, regulatory approvals and manufacturing scale-up; its collaboration strategy (notably with large partners) aims to de‑risk development and broaden commercial reach. As of the provided market data the company has a market capitalisation of about $6.58 billion. Investors should note the typical biotech profile: meaningful upside if trials succeed, but significant clinical, regulatory and execution risk if they do not. Research and development spending is a major cash use and share prices can be volatile around trial readouts. This summary is educational only and not personal investment advice; consider suitability, diversification and your risk tolerance before acting.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying CRISPR Therapeutics' stock with a target price of $69.67, indicating growth potential.
Financial Health
CRISPR Therapeutics is generating modest revenue and cash flow, with a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CRSP
Investment Opportunities in RNA Therapeutics Explained
Eli Lilly's $2.4 billion acquisition of Orna Therapeutics signals a major bet on circular RNA and in vivo cell engineering. This theme focuses on the broader ecosystem of companies developing the next-generation platforms and delivery technologies essential for advancing genetic medicine.
Published: 10 February 2026
Explore BasketBeyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: 5 August 2025
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: 30 July 2025
Explore BasketGene Therapy's Competitive Shift
The European Medicines Agency's recent rejection of Sarepta Therapeutics' gene therapy creates a potential opening for its competitors. This theme focuses on the biopharmaceutical companies that stand to benefit from this regulatory hurdle in the Duchenne muscular dystrophy market.
Published: 25 July 2025
Explore BasketPioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: 21 July 2025
Explore BasketBiotech's IP Moat
This carefully selected group of stocks features biotech companies with powerful patent portfolios. These firms are at the forefront of medical innovation in areas like gene editing and mRNA technology, where intellectual property can create lasting competitive advantages and drive long-term growth.
Published: 11 July 2025
Explore BasketMarket Greed
Ride the wave of investor optimism with this carefully selected group of high-growth companies. Our professional analysts have identified businesses positioned to deliver amplified returns when market sentiment is bullish and risk appetite is high.
Published: 18 June 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: 17 June 2025
Explore BasketPatient Platforms
This carefully curated collection features companies building the technological foundations that will power innovation for decades to come. Our analysts have identified businesses creating essential infrastructure in genomics, AI, robotics, and advanced computing—platforms that could define their industries and generate substantial long-term returns.
Published: 17 June 2025
Explore BasketBio-Hacking Portfolio
Discover companies at the cutting edge of human optimization, where biology meets technology. These carefully selected stocks represent innovators developing data-driven solutions for personalized health, enhanced performance, and extended longevity.
Published: 17 June 2025
Explore BasketDavid Vs. Goliath
This carefully curated selection features ambitious companies challenging industry giants with innovative strategies. Our experts have identified these potential disruptors that leverage cutting-edge technology and smarter business models to take on established market leaders.
Published: 17 June 2025
Explore BasketNew Moon Portfolio
This collection represents the very beginning of the next technological cycle. These carefully selected companies are sowing the seeds of future industries, giving you early exposure to disruptive innovators poised for exponential growth as their technologies reshape our world.
Published: 17 June 2025
Explore BasketDeep Future
This collection features companies pioneering revolutionary technologies that could transform our world in the decades ahead. Carefully selected by our analysts, these stocks represent visionary enterprises working on quantum computing, next-generation energy, and genetic medicine breakthroughs.
Published: 17 June 2025
Explore BasketSolar Eclipse Black Box
This carefully selected group of stocks represents breakthrough technologies developing in the shadows before their dramatic market emergence. Our professional analysts have identified companies pioneering quantum computing, gene editing, and other innovations with potential for explosive growth once they step into the spotlight.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Watch
Trial readouts and regulatory decisions can be major share‑price drivers; outcomes are binary and performance can vary materially.
Partnerships & Scale
Collaborations with larger pharma can provide funding, expertise and commercial reach, though deal terms and reliance on partners are important to assess.
Scientific Potential vs Risk
CRISPR’s technology could transform treatments for genetic diseases, but scientific, manufacturing and regulatory hurdles mean outcomes are uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
